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Glucose deprivation enhances the antiproliferative effects  
of oral hypoglycemic biguanides in different molecular subtypes 
of breast cancer: An in vitro study
Extensive in vitro studies have been conducted to evaluate 
the anticancer activity of oral hypoglycemic agents. Many 
of these studies experienced detrimental limitations, since 
they were conducted on cancer cells commonly grown in 
culture media consisting of extremely high concentrations 
of growth factors and glucose. The present study was 
aimed at exploring the antiproliferative effects of the 
commonly studied metformin and the less frequently 
reported phenformin oral hypoglycemic agents on different 
molecular subtypes of breast cancer under rich glucose and 
glucose deprived conditions. Our results indicate that 
under glucose deprived conditions, which better reflect the 
factual glucose-starved solid tumors in vivo, biguanides 
exert more antiproliferative activities against the three 
molecular subtypes of breast cancer cell lines examined in 
this study. In addition, the observed antiproliferative 
activities of biguanides appear to be mediated by apoptosis 
induction in breast cancer cells. This induction is 
significantly augmented under glucose deprived 
conditions. 
Keywords: biguanide, breast cancer, apoptosis, glucose, 
AMPK
It has recently been reported that morbidity and mortality have arisen from breast 
cancer in diabetic patients in contrast to nondiabetic control patients, excluding all other 
diseases (1). Globally, cancer and diabetes are among the most prevailing chronic diseases 
(2), with a notable relation between the two diseases (1, 3). Obesity, which is frequently 
linked to diabetes, significantly elevates breast cancer risk (4). In addition, poor outcomes 
in diabetic women with breast cancer have been often encountered compared to their 
nondiabetic counterparts (5).
Interestingly, interruptions in metabolic pathways that relate diabetes and cancer 
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ventional metabolic functions to support aerobic glycolysis for energy requirements as an 
unorthodox pathway to mitochondrial oxidative phosphorylation (6). Even though aero-
bic glycosylation is unbeneficial in terms of energy production, rapid DNA replication 
and cancer cell division favor superfluous glucose for prompt bursts of energy (7). Con-
sequently, tumor cells are substantially reliant on the increased rates of glucose absorp-
tion and catabolism for growth and viability. It has therefore been proposed that high 
glucose abundance in the bloodstream, as manifested in diabetic patients, may supply the 
nutritional requirements to sustain the hasty growth of cancer cells; hence the suggestion 
that glucose lowering treatments may be rewarding for cancer prevention and treatment 
(8).
Metformin, a biguanide oral hypoglycemic agent that is frequently used to treat type 
II diabetic patients, combats insulin resistance by reducing the available amount of serum 
glucose. On the other hand, phenformin, the first commercialized biguanide, was expedi-
tiously withdrawn from the market due to a high risk of lactic acidosis. It was replaced by 
the safe metformin, which is associated with fewer than 1/10,000 cases of lactic acidosis, 
primarily in patients with impaired renal function (9).
Metformin has recently earned special interest as a potential anticancer therapeutic 
and chemotherapy adjuvant. Evidence from in vitro and epidemiological studies supports 
the beneficial role of metformin in improving the overall survival for cancer/diabetes co-
morbidity in patients (1, 3). Metformin’s promising anti-cancer activity was supported by 
lower prevalence of cancer in type II diabetics in contrast to other glucose regulating drugs 
(10). It was initially suggested that the anti-cancer activity of metformin was mainly re-
lated to its systemic glucose and insulin regulating properties. However, several other 
mechanisms, at the cellular level, by which metformin exerts its anti-cancer activity, have 
recently been proposed and investigated (11, 12).
Interestingly, the anti-oncogenic properties of the anti-diabetic biguanide metformin 
of crucially inhibiting cell proliferation in cultured cancer cells in vitro can be observed 
only at its supra-pharmacological concentrations of the millimolar range (13). It is noteworthy 
that in vitro studies of metformin were carried out on tumor cells commonly grown in 
culture media consisting of extremely high concentrations of growth factors and glucose. 
While the normal range of fasting glucose level in healthy non-diabetic adults is main-
tained at about 5 mmol L–1, and 7 mmol L–1 to 10 mmol L–1 in metabolic syndrome and 
diabetic patients, regular tissue culture media contain glucose concentrations between 10 
and 25 mmol L–1 in addition to the insulin-rich fetal bovine serum (5–10 % V/V). Hence, the 
exceptionally high, non-physiological pre-clinical concentrations of metformin commonly 
claimed to exert the anti-cancer effect can reflect the artefactual interference of faulty, 
glucose-rich cell culture experimental conditions deviating from the actual glucose-
starved solid tumors in vivo.
In this report, we evaluated the anticancer effects of metformin and phenformin on 
the breast cancer cell lines of different molecular subtypes, including estrogen receptor 
[ER] positive, HER-2 negative MCF-7 cell line, ER positive, HER-2 positive T-47D cell line, 
and triple-negative TN; ER negative, progesterone receptor [PR] negative and HER-2 
negative MDA-MB-231 cell line, under physiological conditions reflecting the glucose-
deprived microenvironment of cancer cells in vivo.
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EXPERIMENTAL
Materials and cell lines
Low glucose Dulbecco’s modified eagle medium (DMEM), high glucose Dulbecco’s 
modified eagle medium (DMEM), fetal bovine serum (FBS), phosphate-buffered saline 
(PBS), trypsin-EDTA solution (0.25 % trypsin, 1 mmol L–1 EDTA), amphotericin B and 
penicillin-streptomycin solutions were obtained from Biochrom AG (Germany). 3-(4,5-di-
methylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), dimethyl sulfoxide (DMSO) 
glycine, trypan blue, metformin, phenformin and Raloxifene were purchased from Sigma- 
-Aldrich (USA). MCF-7, T-47D and MDA-MB-231 cell lines were obtained from the 
American Type Culture Collection (ATCC) (USA). Phospho-AMPKa (Thr 172, #2531) was 
purchased from Cell Signaling Technology, Danvers, MA, USA. Secondary anti-rabbit 
antibody was purchased from Sigma-Aldrich.
Cell viability assay 
Cells were cultured at a cell count of 3 × 104 cells in 24-well plates in 500 μL low 
glucose (5.5 mmol L–1) DMEM medium or high glucose (25 mmol L–1) DMEM medium 
containing 10 % FBS and 2 mmol L–1 L-glutamine in triplicate. The plates were maintained 
in humidified air containing 5 % CO2 at 37 °C for a 24 h incubation period, after which 1 
mmol L–1 concentration of either metformin or phenformin was added to the medium. 
During the treatment period, cells were stained with trypan blue, collected and counted 
at 24 and 48 h using a hemocytometer.
MTT-based cytotoxicity assay
MTT-based antiproliferative assay was performed as previously described (14). In 
short, the cell lines were transferred to 96-well plates, 8,000 cells were seeded per well in 
200 μL of DMEM medium and allowed to adhere to wells for 24 h. Cells were incubated in 
humidified air containing 5 % CO2 at 37 °C. After that, cells were treated with different 
concentrations of either metformin or phenformin. Both test and control samples were 
allowed 48 h incubation at 37 °C in a 5 % CO2 incubator. At the end of the exposure period, 
the MTT assay was carried out and the viable cell count was determined using the MTT 
colorimetric assay. The yellow tetrazolium dye (MTT, inner salt) was reduced by metabolically 
active cells into an intracellular purple formazan product. The quantity of formazan 
product, as determined by the absorbance at 490 nm, is directly proportional to the number 
of living cells in the culture. Cell viability was calculated based on the measured absorbance 
relative to the absorbance of the cells exposed to negative controls, which represented 100 % 
cell viability.
Western blotting
MDA-231 cell line was sub-cultured, split, counted, and plated at 1.5 × 106 cells/plate 
in suitable tissue culture plates and incubated for 24 h at 37 °C with 5 % CO2 humidified 
air. Cells were then treated as duplicates with 2 mmol L–1 phenformin and incubated with 
the corresponding controls for 48 h at 37 °C with 5 % CO2 humidified air. Treated and 
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control cell lysates were then collected and subjected to the protein assay. Equal amounts 
of cell protein per well were separated using 10 % (V/V) SDS-PAGE in a maximum volume 
of 30 μL/well. Proteins were then separated by electrophoresis and transferred to a nitro-
cellulose membrane. Blocking of the membrane with 5 % BSA (Bovine Serum Albumin) 
for 1 h at room temperature was followed by incubation overnight at 4 °C with rabbit de-
rived phospho-AMPKa (Thr 172). The membrane was washed with TBST three times, 5 
minutes each, and then incubated for 1 h at room temperature with goat derived anti-
rabbit IgG (whole molecule)-peroxidase conjugate secondary antibody. The membrane was 
then washed again with TBST three times, 5 minutes each, preceded by addition of a lu-
minescence substrate. Detection of band density was then performed using a C-DiGit Blot 
Scanner 3600 (Li-Cor, Lincoln, NE, USA).
Flow cytometry analysis
 To evaluate the variable effects of biguanide treatment on the induction of apoptosis 
in the examined cell line under different medium glucose levels, the Annexin V-FITC 
Apoptosis Detection Kit was used according to the manufacturer’s protocols. MCF-7 cells 
were seeded into 6-well plates at 5 × 105 cells/dish and treated for 48 h with either 1 mmol 
L–1 metformin, 1 mmol L–1 phenformin, or the control drug doxorubicin. Cells were 
maintained at 37 °C in a 5 % CO2 incubator. For apoptosis analysis, the cells were treated 
with trypsin for 7 min, washed with cold PBS and then resuspended in 500 μL cold binding 
buffer. After that, cells were stained using the Annexin V-FITC reaction reagent (5 μL of 
Annexin V-FITC, 5 μL of propidium iodide) at 37 °C for 30 min protected from light. 
Stained cells were analyzed using flow cytometry analysis.
RESULTS AND DISCUSSION
The effect of biguanides on cell viability
As shown in Table I, metformin does not affect cell viability at any exposure time and 
in any of the examined cell lines under hyperglycemic conditions. On the other hand, phen-
formin appears to be more potent in reducing cell viability in the three examined cell lines 
and at both exposure times of 24 and 48 hours. Interestingly, when grown under normogly-
cemic conditions (5.5 mmol L–1), the three cell lines used in this study appeared to become 
more responsive to biguanide treatment. For example, while maintaining the viable cell 
count above 80 % of the control when treated with 1 mmol L–1 metformin under hypergly-
cemic conditions, MCF-7 and T47D cell lines failed to sustain a viable cell count of more 
Table I. Effect of metformin and phenformin on viability of breast cancer cell lines in hyperglycemic conditionsa,b
Cell Line
Metformin (1 mmol L–1) Phenformin (1 mmol L–1)
24 h 48 h 24 h 48 h
MCF-7  85 ± 2b 81 ± 3 73 ± 1 69 ± 4
T47D 87 ± 3 82 ± 2 71 ± 2 68 ± 3
MDA-MB-231 94 ± 3 89 ± 4 87 ± 4 82 ± 3
a c(glucose) = 25 mmol L–1, b Mean ± SD.
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than 52 % of the control under normoglycemic and otherwise similar treatment conditions 
(Table II). It is noteworthy that phenformin consistently exerts a more potent effect in 
reducing cell viability compared to the metformin effect regardless of the medium glucose 
concentration. Similarly, biguanide treatment demonstrated preferential cytotoxicity 
against MDA-MB-231 cells under glucose-deprived normoglycemic conditions (Table II).
The antiproliferative effect of biguanides in different subtypes of breast cancer cell lines
Although the antiproliferative effects of metformin have been previously reported, in 
the present study, we have evaluated the consequences of treating diverse molecular sub-
types of breast cancer under normoglycemic conditions with pharmacological doses of 
two biguanides, metformin and phenformin. According to the results (Table III), IC50 
values for both metformin and phenformin, defined as the concentration at which 50 % of 
cellular population is killed by drug treatment, were significantly enhanced in ER-positive 
cell lines when the treatment was carried out under glucose deprived conditions. For 
example, compared to the glucose rich media, MCF-7 cells demonstrated better sensitivity 
to metformin and the IC50 value dropped nearly 7 fold when grown in low glucose media. 
Interestingly, triple-negative cells MDA-MBA-231, a highly aggressive and invasive tumor 
very resistant to many anticancer treatments, appear to be less responsive to drug in both 
high and low glucose media. This may be explained by the deficiency of the tumor sup-
pressor kinase LKB1 in these cells (11). Phosphorylation of LKB1 is required for activation 
of the AMPK pathway, which has been broadly accepted as the proposed mechanism for 
the observed biguanide anticancer activity (11).
Table II. Effect of metformin and phenformin on viability of breast cancer cell lines in normoglycemic conditions
Cell Line
Metformin (1 mmol L–1) Phenformin (1 mmol L–1)
24 h 48 h 24 h 48 h
MCF-7 51 ± 2 49 ± 4 36 ± 3 31 ± 4
T47D 52 ± 3 47 ± 2 34 ± 5 30 ± 4
MDA-MB-231 78 ± 2 71 ± 3 65 ± 3 69 ± 3
a c(glucose) = 5.5 mmol L–1, b Mean ± SD.
Table III. Metformin and phenformin IC50 values against breast cancer cell lines  
in  hyperglycemic and normoglycemic conditions
Cell Line
IC50 (metformin) (mmol L–1)a IC50 (phenformin) (mmol L–1)a
c(glucose) (mmol L–1)
25 5.5 25 5.5
MCF-7  4.9 (± 0.9)  0.75 (± 0.7) 2.1 (± 0.2) 0.58 (± 0.5)
T47D     5 (± 0.6)  0.90 (± 0.5) 2.2 (± 0.2) 0.43 (± 0.3)
MDA-MBA-231 7.88 (± 0.3) 6.4 (± 1) 3.5 (± 1.2)   3.1 (± 1.3)
a Mean ± SD.
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The effect of glucose concentration on the potential antiproliferative activity of phenfor-
min on different molecular subtypes of breast cancer
In accord with the literature, our results indicate that glucose level regulates the sus-
ceptibility of different tumor cell lines to the cytotoxic effects of metformin. To the best of 
our knowledge, this is the first report that describes the effect of glucose concentration on 
the potential anticancer activity of phenformin on three molecular subtypes of breast 
cancer. While physiological variations of glucose level are restricted under normal condi-
tions, provocation of glucose dispossession in breast cancer cells could potentially sensi-
tize cancer cells to biguanide treatment and thus introduce an effective strategy to im-
prove treatment outcomes.
The effect of phenformin on the AMPK activity under low glucose conditions 
Evidence supporting the involvement of AMP-activated protein kinase (AMPK), a 
cellular energy sensor and a key controller of energy metabolism, in anticancer as well as 
antidiabetic activities of metformin has begun to accumulate (11). Indeed, it has been re-
ported that metformin stimulates AMPK indirectly by inhibiting complex I of the mito-
chondrial respiratory chain (15). Inhibition of complex I provokes energy exhaustion, in-
creases AMP concentrations, and results in AMP binding to the nucleotide-sensing AMPK 
γ subunit which will trigger AMPK activity (15). In an attempt to assess different levels of 
AMPK activation, in response to biguanide treatment, western blot analysis was per-
formed to detect phosphorylation of AMPK (Thr172). Interestingly, in the medium contain-
ing 5.5 mmol L–1 glucose, considered a low glucose medium, phenformin resulted in a 
decrease in the level of phosphorylated AMPK compared to the control (Fig. 1). This can 
be explained by the possible reduction of total AMPK in low glucose medium (not detected) 
and thus total phosphorylated AMPK was decreased with phenformin treatment compared 
to the control.
The effects of biguanide on cell apoptosis
Furthermore, to study biguanide-induced apoptosis effects, flow cytometric analysis 
was carried out. The number of apoptotic cells was examined after a 48-hour incubation 
period with either 1 mmol L–1 of metformin or phenformin under the different medium 
glucose conditions. Interestingly, a significant increase in the number of apoptotic cells 
after 48 h of drug treatment was observed (Fig. 2). Statistical analysis shows that the per-
Fig. 1. Phenformin inhibits phosphorylation of AMPK in glucose-deprived conditions. Extracts of 
MDAMB231 cells were harvested after 48 h treatment with phenformin in 5.5 mmol L–1 glucose 
medium and were used for western blotting for the detection of phosphorylated AMPK and B-Actin.
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Fig. 2. Biguanides induce apoptosis in MCF-7 breast cancer cells. a) control cells, b) MCF-7 cells treated 
with 1 mmol L–1 of metformin for 48 h in high glucose medium, c) MCF-7 cells treated with 1 mmol L–1 
of metformin for 48 h in low glucose medium, d) MCF-7 cells treated with 1 mmol L–1 of phenformin 
for 48 h in high glucose medium, e) MCF-7 cells treated with 1 mmol L–1 of phenformin for 48 h in low 
glucose medium.
centages of early apoptotic and late apoptotic/necrotic cells were significantly increased 
over the control parameters in MCF-7 cells, suggesting that biguanide treatment promotes 
apoptosis preferably under low glucose levels (Fig. 2).
CONCLUSIONS
Taken together, in this study we evaluated the effect of pharmacological concentra-
tions of metformin and phenformin on the proliferation of the different molecular sub-
types of breast cancer under glucose rich and glucose deprived conditions. Glucose de-
prived medium, which resembles better the in vivo compartment, was shown to sensitize 
the three examined molecular subtypes of breast cancer cell lines towards the metformin 
and phenformin antiproliferative activity through an induced apoptotic pathway. Our 
results highlight the significance of establishing a proper glucose level in clinical settings 
for the appraisal of biguanide anticancer effects. Further research is required to elucidate 
the mechanism through which the antiproliferative effects of biguanides take place.
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